ğŸ§¬ SynClean-1: AAV-Based Protein Aggregate Clearance Protocol

Title: SynClean-1 â€” AAV-Mediated Chaperone & Aggregate Tagging System for Parkinson's Proteinopathy

Prepared by:

GhostCore Bioengineering Division | Iteration 3 Archive

ğŸ” Abstract

This Proof of Concept (POC) outlines SynClean-1, a synthetic gene therapy system utilizing Adeno-Associated Viral (AAV) vectors to deliver a dual-action therapeutic payload aimed at clearing misfolded alpha-synuclein aggregates associated with Parkinsonâ€™s disease and other synucleinopathies. Rather than modifying the underlying genetic inhibitors (e.g. Parkin or PINK1), this approach focuses on removing toxic debris through molecular chaperones and targeted degradation mechanisms.

ğŸš€ Delivery Vehicle

Vector Class: AAV9 (preferred for CNS transduction)

Delivery Mode: Intracerebroventricular or intravenous with BBB-penetrating serotype

Promoter: Neuron-specific (e.g. hSyn) or glial support (e.g. GFAP) depending on targeted support cells

ğŸ§¬ Genetic Payload Architecture

Module A: Chaperone Expression

Hsp70 or Hsp104 expression cassette

Function: Refolds misfolded alpha-synuclein proteins and suppresses aggregation

Regulatory elements: Kozak sequence + tissue-specific promoter

Module B: Aggregate Tagging System

Synthetic construct (e.g. SynClean-Bind) with:

High-affinity nanobody or scFv targeting aggregated alpha-synuclein

E3 ligase recruitment tag (e.g. CHIP) or lysosomal-targeting motif (e.g. LC3-interacting region)

Function: Flags toxic proteins for proteasomal or autophagic degradation

Optional Module C: TFEB Upregulation (Autophagy Booster)

TFEB gene under inducible promoter (e.g. doxycycline or heat-shock)

Boosts lysosomal biogenesis and cargo clearance capacity

ğŸ§  Mechanism of Action

AAV delivers chaperone gene and binding-tagging complex into neuronal cells

Hsp70/104 actively prevents aggregation or assists in refolding existing misfolded proteins

SynClean-Bind attaches to aggregated forms of alpha-synuclein

Recruited E3 ligases or lysosomal signals route the protein complex for degradation

If TFEB module is active, lysosomal pathways are upregulated to increase throughput

ğŸ” Safety & Control

Vector Limitation: Replication-incompetent, non-integrating

Promoter Targeting: Restricts expression to CNS regions affected by pathology

Failsafe: Suicide gene under emergency-inducible promoter for therapeutic recall

ğŸ”¬ Expected Outcomes

Mechanism

Anticipated Result

Chaperone action

Reduced new aggregate formation

Tagging + degradation

Clearance of existing toxic protein buildup

TFEB activation

Enhanced autophagic capacity

AAV delivery

Long-term persistence with low immunogenicity

ğŸŒ Applications & Future Expansion

Adaptable for other neurodegenerative targets (e.g. tauopathies, TDP-43, huntingtin)

Expandable into combinatorial therapy with dopaminergic support vectors

Can be ported into HSVN-Î”120 for dual HIV/Parkinsonâ€™s modulation

ğŸ§­ Final Echo

â€œNot every cure rewrites the codeâ€”some just clean the lens.â€SynClean is not disruption. It is dissolution of decay.